HomeCompareTRUMY vs FCPT

TRUMY vs FCPT: Dividend Comparison 2026

TRUMY yields 1.39% · FCPT yields 6.05%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 TRUMY wins by $532.2K in total portfolio value· pulled ahead in Year 6
10 years
TRUMY
TRUMY
● Live price
1.39%
Share price
$13.70
Annual div
$0.19
5Y div CAGR
75.5%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$581.3K
Annual income
$384,516.52
Full TRUMY calculator →
FCPT
FCPT
● Live price
6.05%
Share price
$23.65
Annual div
$1.43
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.1K
Annual income
$5,775.28
Full FCPT calculator →

Portfolio growth — TRUMY vs FCPT

📍 TRUMY pulled ahead of the other in Year 6

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTRUMYFCPT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TRUMY + FCPT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TRUMY pays
FCPT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TRUMY
Annual income on $10K today (after 15% tax)
$117.88/yr
After 10yr DRIP, annual income (after tax)
$326,839.04/yr
FCPT
Annual income on $10K today (after 15% tax)
$514.49/yr
After 10yr DRIP, annual income (after tax)
$4,908.99/yr
At 15% tax rate, TRUMY beats the other by $321,930.05/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TRUMY + FCPT for your $10,000?

TRUMY: 50%FCPT: 50%
100% FCPT50/50100% TRUMY
Portfolio after 10yr
$315.2K
Annual income
$195,145.90/yr
Blended yield
61.92%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on FCPT right now

TRUMY
No analyst data
Altman Z
4.2
Piotroski
7/9
FCPT
Analyst Ratings
5
Buy
10
Hold
Consensus: Hold
Price Target
$27.00
+14.2% upside vs current
Range: $25.00 — $29.00
Altman Z
1.4
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TRUMY buys
0
FCPT buys
0
No recent congressional trades found for TRUMY or FCPT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTRUMYFCPT
Forward yield1.39%6.05%
Annual dividend / share$0.19$1.43
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR75.5%15.8%
Portfolio after 10y$581.3K$49.1K
Annual income after 10y$384,516.52$5,775.28
Total dividends collected$542.2K$24.1K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: TRUMY vs FCPT ($10,000, DRIP)

YearTRUMY PortfolioTRUMY Income/yrFCPT PortfolioFCPT Income/yrGap
1$10,943$243.39$11,401$700.92$458.00FCPT
2$12,146$436.87$13,064$864.84$918.00FCPT
3$13,792$795.32$15,051$1,072.48$1.3KFCPT
4$16,238$1,481.20$17,442$1,337.22$1.2KFCPT
5$20,236$2,860.42$20,340$1,677.08$104.00FCPT
6← crossover$27,499$5,846.46$23,880$2,116.57+$3.6KTRUMY
7$42,455$13,031.07$28,241$2,689.36+$14.2KTRUMY
8$78,424$32,998.00$33,660$3,442.07+$44.8KTRUMY
9$183,893$99,978.77$40,456$4,439.95+$143.4KTRUMY
10$581,282$384,516.52$49,063$5,775.28+$532.2KTRUMY

TRUMY vs FCPT: Complete Analysis 2026

TRUMYStock

Terumo Corporation engages in the manufacture and sale of medical products and equipment worldwide. The company operates through three segments: Cardiac and Vascular Company, Medical Care Solutions Company, and Blood and Cell Technologies Company. The Cardiac and Vascular Company segment offers angiographic guidewires, angiographic catheters, introducer sheaths, vascular closure devices, PTCA balloon catheters, coronary stents, self-expanding peripheral stents, intravascular ultrasound systems, imaging catheters, and others; coils, stents, and intrasaccular devices for treating cerebral aneurysm; embolization systems, aspiration catheters, and clot retrievers for treating ischemic stroke and others; oxygenators, cardio-pulmonary bypass systems, and others; and artificial vascular and stent grafts. The Medical Care Solutions Company segment provides syringes, infusion pumps, syringe pumps, infusion lines, I.V. solutions, peritoneal dialysis fluids, pain management and nutritious food products, adhesion barriers, and others; blood glucose monitoring systems, disposable needles for pen-injector, insulin patch pumps, blood pressure monitors, digital thermometers, and others; and contract manufacturing of prefilled syringes, devices to pharmaceutical companies for use in drug kits, such as prefillable syringes, needles for pharmaceutical packaging business, and others. The Blood and Cell Technologies Company segment offers blood bags, component collection systems, automated blood processing systems, pathogen reduction systems, centrifugal apheresis systems, cell expansion systems, and others. The company was formerly known as Sekisen Ken-onki Corporation and changed its name to Terumo Corporation in October 1974. Terumo Corporation was incorporated in 1921 and is headquartered in Tokyo, Japan.

Full TRUMY Calculator →

FCPTREIT

FCPT, headquartered in Mill Valley, CA, is a real estate investment trust primarily engaged in the acquisition and leasing of restaurant properties. The Company seeks to grow its portfolio by acquiring additional real estate to lease, on a net basis, for use in the restaurant and retail industries.

Full FCPT Calculator →
📬

Get this TRUMY vs FCPT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TRUMY vs SCHDTRUMY vs JEPITRUMY vs OTRUMY vs KOTRUMY vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.